{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"36.94","value":"0"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"70.76","value":"0"},{"groupId":"OG002","lowerLimit":"27.80","upperLimit":"68.69","value":"48"},{"groupId":"OG003","lowerLimit":"14.95","upperLimit":"53.50","value":"32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"25"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a partial response (PR) rate or better (stringent complete response \\[sCR\\] + complete response \\[CR\\] + very good partial response \\[VGPR\\] + PR) during the study as defined by international myeloma working group (IMWG) uniform response criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 hours. CR: negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow. sCR: CR+normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. VGPR:serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG000","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG001","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG002","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG003","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The SAS included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573 and with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Up to 34.7 months in Part 2","title":"Part 2: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}